May use to predict survival in patients treated for metastatic breast, prostate, and colorectal cancers. May use to evaluate response to therapy.
Immunomagnetic Separation/Immunofluorescent Stain/Computer Assisted Analysis
New York DOH Approval Status
If the patient is on doxorubicin therapy, allow at least 1 week following administration of a dose of doxorubicin before blood draw.
2 CellSave Preservative tubes (ARUP supply # 44867) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787. (Min: 8 mL per tube)
Transport 20 mL whole blood. (Min: 16 mL)
Specimens not collected in the CellSave tube or collected in expired CellSave tubes. Short draws.
Submit with Order: Source of metastatic cancer. This assay is FDA approved only for breast, colorectal, or prostate metastatic cancers; other types will not be tested.
Ambient: 4 days; Refrigerated: Unacceptable; Frozen: Unacceptable
Refer to report.
For additional information, refer to the Breast Cancer Management Assays, Prostate Cancer, or Colorectal Cancer topic at arupconsult.com.
The CellSearch™ Circulating Tumor Cell kit is intended for the quantification of circulating tumor cells (CTC) of epithelial origin for metastatic breast, colon, or prostate cancer, in whole blood. This assay can be used to predict progression free and overall survival in patients treated for metastatic cancer.
The results of a CellSearch test should be interpreted with caution if specimens are drawn within 7 days of administration of doxorubicin therapy.
|Component Test Code*||Component Chart Name||LOINC|
|0093400||Circulating Tumor Cell Number||67568-6|
|0093401||Patient History - Metastatic Cancer Type||63929-4|
|2007444||EER Circulating Tumor Cell Count||11526-1|
- Cell Search
- Circulating Tumor Cells, Breast, Colon, Prostate